Baseline characteristics
| Characteristic . | All patients (N = 46) . |
|---|---|
| Age, median (range), y | 61.0 (28.0-87.0) |
| ≥65, n (%) | 20 (43.5) |
| Male, n (%) | 28 (60.9) |
| Race, n (%) | |
| White | 41 (89.1) |
| Black or African American | 2 (4.3) |
| Asian | 1 (2.2) |
| Not reported | 2 (4.3) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 3 (6.5) |
| Not Hispanic or Latino | 43 (93.5) |
| Prior anticancer therapies, median (range) | 3 (1∗-9) |
| ECOG PS, n (%)† | |
| 0 | 28 (60.9) |
| 1 | 16 (34.8) |
| iNHL type, n (%) | |
| FL | 42 (91.3) |
| MZL | 4 (8.7) |
| Stage at initial diagnosis, n (%) | |
| I-II | 6 (13.0) |
| III-IV | 29 (63.0) |
| Unknown | 11 (23.9) |
| Rituximab refractory, n (%)‡ | |
| Any regimen | 30 (65.2) |
| Last regimen | 23 (50.0) |
| Refractory to last regimen, n (%) | 29 (63.0) |
| Primary refractory, n (%)§ | 15 (32.6) |
| Prior autologous transplant, n (%) | 10 (21.7) |
| Prior anticancer therapies, median (range) | 3 (1-9) |
| Anti-CD20 monoclonal antibodies, n (%) | 45 (97.8) |
| Chemotherapy, n (%) | 45 (97.8) |
| Steroids, n (%) | 38 (82.6) |
| Targeted therapy, n (%) | 19 (41.3) |
| Stem cell therapy, n (%) | 10 (21.7) |
| Antibody–drug conjugate, n (%) | 8 (17.4) |
| Immunotherapy, n (%) | 8 (17.4) |
| PD-1/PD-L1 inhibitors, n (%) | 4 (8.7) |
| Cytoprotectants, n (%) | 1 (2.2) |
| POD24, n (%) | 26 (56.5) |
| Time from diagnosis to study entry, median (range), mo | 75.2 (7.7-272.5)ǁ |
| Characteristic . | All patients (N = 46) . |
|---|---|
| Age, median (range), y | 61.0 (28.0-87.0) |
| ≥65, n (%) | 20 (43.5) |
| Male, n (%) | 28 (60.9) |
| Race, n (%) | |
| White | 41 (89.1) |
| Black or African American | 2 (4.3) |
| Asian | 1 (2.2) |
| Not reported | 2 (4.3) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 3 (6.5) |
| Not Hispanic or Latino | 43 (93.5) |
| Prior anticancer therapies, median (range) | 3 (1∗-9) |
| ECOG PS, n (%)† | |
| 0 | 28 (60.9) |
| 1 | 16 (34.8) |
| iNHL type, n (%) | |
| FL | 42 (91.3) |
| MZL | 4 (8.7) |
| Stage at initial diagnosis, n (%) | |
| I-II | 6 (13.0) |
| III-IV | 29 (63.0) |
| Unknown | 11 (23.9) |
| Rituximab refractory, n (%)‡ | |
| Any regimen | 30 (65.2) |
| Last regimen | 23 (50.0) |
| Refractory to last regimen, n (%) | 29 (63.0) |
| Primary refractory, n (%)§ | 15 (32.6) |
| Prior autologous transplant, n (%) | 10 (21.7) |
| Prior anticancer therapies, median (range) | 3 (1-9) |
| Anti-CD20 monoclonal antibodies, n (%) | 45 (97.8) |
| Chemotherapy, n (%) | 45 (97.8) |
| Steroids, n (%) | 38 (82.6) |
| Targeted therapy, n (%) | 19 (41.3) |
| Stem cell therapy, n (%) | 10 (21.7) |
| Antibody–drug conjugate, n (%) | 8 (17.4) |
| Immunotherapy, n (%) | 8 (17.4) |
| PD-1/PD-L1 inhibitors, n (%) | 4 (8.7) |
| Cytoprotectants, n (%) | 1 (2.2) |
| POD24, n (%) | 26 (56.5) |
| Time from diagnosis to study entry, median (range), mo | 75.2 (7.7-272.5)ǁ |
MZL, marginal zone lymphoma; PD-1/PD-L1, programmed death receptor 1/programmed death-ligand 1.
The patient with only 1 prior line of therapy was a protocol deviation according to inclusion/exclusion criteria.
ECOG PS was missing for 2 patients.
Defined as failure to achieve an objective response or progression during any previous rituximab-containing regimen (monotherapy or in combination) or progression within 6 months of last rituximab dose.
Defined as either no response to treatment, progression during the first treatment regimen, or progression within 6 months of the last dose of the first treatment regimen. Patients discontinuing the first treatment regimen because of toxicity are not considered to have primary refractory disease.
Seven patients were missing their original diagnosis date.